Fig. 1 · Structure

Documents & Downloads

Carfilzomib (PR-171)

Cat. No. A11278 CAS 868540-17-4

Proteasome inhibitor

PR-171 (Carfilzomib) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.

In Stock

Publications for Carfilzomib

9 publications citing this product

  1. Alireza Saedi, .et al. , J Prev Complement Med, 2025, 4(1): 26-34
  2. Mohammad Reza Hajinezhad, .et al. , Discov Nano, 2025, Aug 14;20(1):135 PMID: 40804566
  3. Zahra Mirzaei, .et al. , BMC Complement Med Ther, 2025, Jan 22;25(1):15 PMID: 39844241
  4. Andrew Thorne, .et al. , PLoS One, 2023, Jun 8;18(6):e0286783 PMID: 37289679
  5. Mahmood Barani, .et al. , J Drug Deliv Sci Technol, 2023, 81: 104268
  6. Ori Kalid, .et al. , Chem Biol Drug Des, 2022, Mar 24 PMID: 35322538
  7. Abbas Rahdar, .et al. , Journal of Molecular Liquids, 2022, 346: 118271
  8. Sadegh Zarei, .et al. , J Appl Biotechnol Rep, 2019, June;6(2):45-49
  9. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Carfilzomib (PR-171) preferentially inhibits chymotrypsin-like proteasome activity. In ANBL-6 myeloma-cell extracts, inhibition exceeded 80% at concentrations of 10 nM and above. Cellular profiling favored β5 and β5i engagement at low exposure, while higher concentrations or longer exposure broadened binding to other catalytic subunits. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Proteasome (ANBL-6 cells) 5 nM

Cellular Effect

Cell Line Activity Value Description Reference
A-431 IC50 23.8 nM Antiproliferative activity against human A431 cells after 72 hrs by oxyluciferin luminescence assay [PMID: 26231162]
A549 IC50 43.3 nM Antiproliferative activity against human A549 cells after 72 hrs by MTS assay [PMID: 30639896]
CCRF-CEM IC50 6.1 nM Antiproliferative activity against human CCRF-CEM cells after 72 hrs by oxyluciferin luminescence assay [PMID: 26231162]
HCT-116 IC50 19.3 nM Antiproliferative activity against human HCT116 cells after 72 hrs by oxyluciferin luminescence assay [PMID: 26231162]
HCT-116 IC50 9.6 nM Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay [PMID: 30639896]
LP-1 IC50 22.7 nM Antiproliferative activity against human LP-1 cells after 72 hrs by MTS assay [PMID: 30639896]
MCF7 IC50 0.0041 μM Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay [PMID: 30165344]
MDA-MB-231 IC50 0.0044 μM Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay [PMID: 30165344]
MES-SA IC50 18 nM Cytotoxicity against human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay [PMID: 19348473]
MES-SA IC50 413 nM Cytotoxicity against multidrug resistance transporter expressing doxorubicin resistant human MESSA cells assessed as cell viability after 72 hrs by CellTiter-Glo luminescent assay [PMID: 19348473]
MGC-803 IC50 934 nM Antiproliferative activity against human MGC803 cells after 72 hrs by MTS assay [PMID: 30639896]
MM1.S IC50 < 1 nM Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay [PMID: 30611983]
MM1.S IC50 1.5 nM Cytotoxicity against human MM1S cells measured after 72 hrs by MTS assay [PMID: 28027531]
MM1.S IC50 1.5 nM Antiproliferative activity against human MM1S cells measured after 72 hrs by MTS assay [PMID: 27765408]
MM1.S IC50 14.35 nM Antiproliferative activity against human MM1.S cells assessed as cell growth inhibition measured after 72 hrs by MTT assay [PMID: 33223460]
MM1.S IC50 2.3 nM Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay [PMID: 30639896]
MOLT-4 IC50 5.1 nM Inhibition of chymotrypsin-like activity of 20S proteasome in human MOLT4 cells after 1 hr by CellTiter-Glo luminescent assay [PMID: 19348473]
NCI-H23 IC50 0.018 μM Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay [PMID: 30964987]
NCI-H727 IC50 0.6102 μM Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay [PMID: 30964987]
NCI-H929 IC50 116.1 nM Antiproliferative activity against human NCI-H929 cells after 72 hrs by MTS assay [PMID: 30639896]

20 records · Scroll to view more

Carfilzomib (PR-171) Research Summary

This section summarizes 2 in vitro studies and 3 in vivo studies of Carfilzomib (PR-171) from 3 published references.

Carfilzomib (PR-171) In Vitro Studies

In RPMI 8226 and ANBL-6 myeloma cells, 24-hour continuous carfilzomib exposure produced WST-1 viability IC50 values <5 nM. A 1-hour pulse followed by recovery also inhibited viability but required higher concentrations. DNA fragmentation increased in four myeloma lines, supporting an apoptotic response whose magnitude varied by cell line. [1]

Proteasome catalytic activity and subunit selectivity

Biochemical assay · ANBL-6 myeloma-cell extracts (20S catalytic activity) and intact ANBL-6 cells (subunit target profiling). [1]

Carfilzomib preferentially inhibited chymotrypsin-like activity and engaged β5/β5i at low exposure. Selectivity depended on concentration and exposure time: additional catalytic subunits were engaged at higher concentrations or longer exposure.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Chymotrypsin-like 20S proteasome activity in ANBL-6 extractsinhibition >80% at 10 nM and above[1]
Cellular proteasome subunit engagementselectivity Preferential β5 and β5i binding after 1-hour exposure; β1/β2/β1i/β2i engagement at concentrations >1 μM[1]
Broader subunit binding with prolonged exposurequalitative After 5-hour pretreatment, increased binding to additional subunits, with maximal binding reported at 50 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Extract assay: 0.1–250 nM shown in Figure 1B. Intact-cell ELISA: 0.001–10 μM. Competitive-binding panel: 10, 25 and 50 nM.
Exposure duration
ELISA: 1-hour drug exposure. Competitive binding: 5-hour drug pretreatment followed by 2-hour probe incubation.
Method
Fluorogenic activity assay and two complementary cellular subunit-profiling assays.
Vehicle
DMSO; stock-method final vehicle concentration did not exceed 0.5% (vol/vol).
Reported limits
Extract-assay drug incubation time and sample replicate counts are not specified in the retrieved main-text assay description/caption; referenced assay protocol was not acquired. No kinetic irreversibility constant is extracted.
Methods and source locations

Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: carfilzomib

Supports named carfilzomib target pharmacology, with exposure-dependent selectivity; no claim of Adooq product testing.

Figure 1A-D and captions; Methods: Measurement of 20S proteasome activity, ELISA subunit profiling and competitive binding; Results: Impact of carfilzomib on the constitutive and immunoproteasome

Chymotrypsin-like 20S proteasome activity in ANBL-6 extracts: Fluorogenic peptide substrate hydrolysis; 10 μg extract protein per reaction. Figure 1B bars are mean with SD; replicate count is not specified in its caption. — Results: Impact of carfilzomib on the constitutive and immunoproteasome; Figure 1B and caption

Cellular proteasome subunit engagement: Active-site probe competition and subunit-specific ELISA; activity expressed relative to vehicle control. Figure 1C error bars are SD. — Figure 1C; Methods: Enzyme-linked immunosorbent assay for subunit profiling; Results: Impact of carfilzomib on the constitutive and immunoproteasome

Broader subunit binding with prolonged exposure: Competition with dansyl-linked vinyl sulfone probe followed by immunoblotting; actin control. No exact occupancy was digitized. — Figure 1D and caption; Results: Impact of carfilzomib on the constitutive and immunoproteasome

Continuous and pulse exposure in myeloma cells

Cell-based study · RPMI 8226 and ANBL-6 for WST-1 response; RPMI 8226, ANBL-6, U266 and KAS-6/1 for DNA fragmentation. [1]

Continuous exposure reduced WST-1 viability at lower concentrations than a 1-hour pulse followed by recovery. DNA fragmentation increased in all four myeloma lines, with differing magnitude.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
24-hour WST-1 viability response in RPMI 8226 and ANBL-6IC50 <5 nM in both cell lines[1]
WST-1 viability after transient exposurequalitative Dose-dependent inhibition after a 1-hour pulse; higher concentrations required than continuous exposure[1]
Apoptotic DNA fragmentation in four myeloma cell linesqualitative Increased DNA fragmentation versus DMSO control, with cell-line-dependent magnitude[1]

Literature-Reported Treatment Conditions

Treatment concentration
WST-1: increasing concentrations shown up to 25 nM continuously or 500 nM by pulse. DNA-fragmentation doses are separately specified in the measurement record.
Exposure duration
WST-1: 24-hour continuous treatment or 1-hour pulse followed by 24-hour recovery in drug-free medium. Pulse DNA fragmentation: 1-hour treatment then 24-hour recovery.
Method
Carfilzomib alone; WST-1 metabolic viability endpoint plus apoptosis-specific DNA fragmentation.
Vehicle
DMSO; final vehicle concentration did not exceed 0.5% (vol/vol).
Reported limits
Figure 2 error bars are SD, but replicate counts are not specified in the caption. Continuous DNA-fragmentation exposure duration is not separately unambiguous in the selected description; no exact fold changes extracted.
Methods and source locations

Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: carfilzomib

Cell-line effects under the reported exposure schedules; these are neither clinical doses nor direct cell counts.

Figure 2A-D and caption; Methods: Cell models/experimental conditions, Cell proliferation assay, Apoptotic DNA fragmentation assay; Results: Antiproliferative and proapoptotic impact of carfilzomib

24-hour WST-1 viability response in RPMI 8226 and ANBL-6: WST-1 relative to parallel vehicle-treated cells; IC50 interpolated by linear spline. The value is explicitly reported in Results, not digitized from the curves. — Results: Antiproliferative and proapoptotic impact of carfilzomib; Figure 2A and caption; Methods: Cell proliferation assay

WST-1 viability after transient exposure: WST-1 after recovery in drug-free medium; Figure 2C. No exact pulse IC50 inferred. — Figure 2C and caption; Results: Antiproliferative and proapoptotic impact of carfilzomib

Apoptotic DNA fragmentation in four myeloma cell lines: DNA fragmentation ELISA. Continuous doses: 10 nM for RPMI 8226/ANBL-6 and 5 nM for U266/KAS-6/1; pulse doses per Methods: 300 nM for RPMI 8226/ANBL-6 and 100 nM for U266/KAS-6/1. Error bars are SD. — Figure 2B,D and caption; Methods: Apoptotic DNA fragmentation assay; Results: Antiproliferative and proapoptotic impact of carfilzomib

Carfilzomib (PR-171) In Vivo Studies

In SHP77 small-cell lung cancer xenografts, carfilzomib monotherapy delayed tumor growth and prolonged survival versus vehicle. Adding cisplatin did not produce a significant survival advantage over vehicle, and two mice died during the first week of combination treatment; the authors judged these deaths likely drug-related. [2]

In PER-785 and PER-826 infant KMT2A-rearranged ALL xenografts, carfilzomib at the study-specific maximum tolerated dose of 2.0 mg/kg did not significantly prolong event-free survival versus vehicle. Dose finding in PER-785 mice showed toxicity at ≥2.5 mg/kg and early euthanasia at 4.0 mg/kg. These findings limit extrapolation across leukemia models. [3]

SHP77 xenograft efficacy and combination limits

Animal study · Female scid mice with established SHP77 small-cell lung cancer flank tumors; randomized at mean tumor volume 200–300 mm³; n = 8 per group. [2]

Carfilzomib monotherapy delayed tumor growth and prolonged survival versus vehicle. Cisplatin and the combination delayed growth without significant survival benefit versus vehicle. The combination produced two early deaths judged likely drug-related.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival of SHP77 tumor-bearing mice versus vehiclelog-rank p values Carfilzomib: p = 0.0092; cisplatin: p = 0.6005; combination: p = 0.1207[2]
Early deaths in combination-treated micecount 2 mice within the first week[2]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Carfilzomib monotherapy
3 mg/kg during the first week, then 5 mg/kg.
Vehicle-only group.Tumor growth delay and survival benefit versus vehicle; log-rank p = 0.0092.[2]
Cisplatin monotherapy comparator
4 mg/kg cisplatin.
Vehicle-only group.Tumor growth delay without significant survival advantage; log-rank p = 0.6005.[2]
Carfilzomib plus cisplatin
Carfilzomib 3 mg/kg in week 1 then 5 mg/kg; cisplatin 4 mg/kg.
Vehicle-only and single-agent groups.Tumor growth delay; no significant survival advantage versus vehicle (log-rank p = 0.1207). Two mice died in the first week, judged likely drug-related.[2]
Carfilzomib monotherapy
Model: Female scid mice bearing SHP77 flank xenografts; n = 8 per group.
Route: Intravenous
Frequency: Two consecutive days each week.
Treatment course: Continued until death or sacrifice; treatment began on day 20 in Figure 4.
Vehicle: Composition of in vivo vehicle not specified in selected methods.
Reported limits: No numerical tumor-growth inhibition percentage or median survival is extracted.
Cisplatin monotherapy comparator
Model: Female scid mice bearing SHP77 flank xenografts; n = 8 per group.
Route: Intraperitoneal
Frequency: Once weekly.
Treatment course: 3 weeks.
Vehicle: Cisplatin stock in saline; in vivo control vehicle composition not specified.
Reported limits: Stock solvent does not establish composition of the matched in vivo control.
Carfilzomib plus cisplatin
Model: Female scid mice bearing SHP77 flank xenografts; n = 8 per group.
Route: Carfilzomib intravenous; cisplatin intraperitoneal.
Frequency: Carfilzomib on days 1 and 2 each week; cisplatin on day 5.
Treatment course: Cisplatin for 3 weeks; carfilzomib schedule as in monotherapy.
Vehicle: In vivo vehicle composition not specified in selected methods.
Reported limits: No formal combination-versus-carfilzomib p value is supplied here; no synergy claimed.
Methods and source locations

Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: CFZ

Named-compound xenograft findings with a formulation-reproducibility limitation; no clinical or Adooq lot equivalence.

Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption

Survival of SHP77 tumor-bearing mice versus vehicle: Kaplan–Meier analysis; log-rank (Mantel–Cox) test; exact p values read from Figure 4B-D. Mice were euthanized at tumor volume 2000 mm³ or tumor necrosis. — Figure 4B-D; caption; Methods: In vivo SHP77 xenograft studies

Early deaths in combination-treated mice: Reported in Results as likely drug-related, not a mechanistically adjudicated cause of death. — Results: In vivo growth inhibition and survival

Carfilzomib monotherapy · Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption

Cisplatin monotherapy comparator · Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption

Carfilzomib plus cisplatin · Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption

Dose finding and leukemia burden in PER-785 mice

Animal study · Female NOD/SCID mice bearing PER-785 infant KMT2A-rearranged ALL; randomized seven groups with nominal n = 5 per group. [3]

The authors selected 2.0 mg/kg as the maximum tolerated dose. Doses ≥2.5 mg/kg produced clinical toxicity; the 4.0 mg/kg group required early euthanasia. The measured leukemia burden was not reduced versus vehicle at the scheduled endpoint.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Dose-limiting morbidityreported MTD 2.0 mg/kg[3]
Human CD19+CD45+ leukemia cells in bone marrow, spleen and peripheral bloodqualitative No reduction versus vehicle at the defined endpoint[3]

Conditions shared by the study groups

Route
Intravenous tail-vein injection.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Carfilzomib dose range
1.5, 2.0, 2.5, 3.0 or 3.5 mg/kg.
Vehicle control.No reduction in leukemia burden at the endpoint; clinical toxicities reported at ≥2.5 mg/kg.[3]
High-dose tolerability limit
4.0 mg/kg.
Vehicle control and lower doses.Early euthanasia due to excessive morbidity.[3]
Carfilzomib dose range
Model: Female NOD/SCID PER-785 xenografts; nominal n = 5 per dose group.
Frequency: Days 1, 2, 8, 9, 15 and 16.
Treatment course: 3 weeks; treatment commenced after a 12-day engraftment period.
Vehicle: Aqueous Captisol or 2-hydroxypropyl-β-cyclodextrin; cohort assignment unspecified.
Reported limits: Nominal n = 5 differs from visible plotted counts in some treated groups; do not infer exact attrition causes.
High-dose tolerability limit
Model: Female NOD/SCID PER-785 xenografts; nominal n = 5.
Frequency: Planned days 1, 2, 8, 9, 15 and 16.
Treatment course: Stopped before completion because of excessive morbidity.
Vehicle: Aqueous cyclodextrin formulation; exact choice unspecified.
Reported limits: Exact completed dose count and individual euthanasia times are not extracted; this group is not plotted in Figure 3.
Methods and source locations

Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: carfilzomib

Model-specific mouse findings; exact cyclodextrin assignment remains unknown. No salt conversion or Adooq material validation.

Methods: Assessment of In Vivo Efficacy; Results: Carfilzomib Displays Toxicity In Vivo...; Figure 3 and caption

Dose-limiting morbidity: Clinical observation: ≥2.5 mg/kg caused weight loss, diarrhea, shortness of breath, slower movement and injection-site swelling; 4.0 mg/kg required euthanasia before treatment completion. — Results: Carfilzomib Displays Toxicity In Vivo...; Methods: Assessment of In Vivo Efficacy

Human CD19+CD45+ leukemia cells in bone marrow, spleen and peripheral blood: Flow cytometry 3 weeks after treatment began. Figure 3 depicts 1.5–3.5 mg/kg groups and vehicle; caption states n = 5 per group, while fewer points are visible in some treated groups. Error bars: mean ± SEM. — Figure 3 image/caption; Results toxicity section; Methods: Assessment of In Vivo Efficacy

Carfilzomib dose range · Methods: Assessment of In Vivo Efficacy; Results: Carfilzomib Displays Toxicity In Vivo...; Figure 3 and caption

High-dose tolerability limit · Methods: Assessment of In Vivo Efficacy; Results: Carfilzomib Displays Toxicity In Vivo...; Figure 3 and caption

Low-burden infant-ALL xenograft survival

Animal study · Female NOD/SCID mice bearing PER-785 or PER-826 infant KMT2A-rearranged ALL; randomized carfilzomib and vehicle groups; n = 8 per group for each model. [3]

Carfilzomib at 2.0 mg/kg did not provide a significant event-free survival benefit over vehicle in either model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Event-free survival in PER-785 and PER-826 xenograftsqualitative No significant survival benefit versus vehicle in either model[3]

Conditions shared by the study groups

Route
Intravenous tail-vein injection.
Frequency
Days 1, 2, 8, 9, 15 and 16.
Vehicle
Aqueous cyclodextrin formulation; exact choice unspecified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PER-785 monotherapy
2.0 mg/kg.
Vehicle control; n = 8.No significant survival benefit.[3]
PER-826 monotherapy
2.0 mg/kg.
Vehicle control; n = 8.No significant survival benefit.[3]
PER-785 monotherapy
Model: Female NOD/SCID PER-785 xenografts; n = 8 per group.
Treatment course: Started day 12 after cell injection, corresponding to 1% human CD19+CD45+ cells in bone marrow.
Reported limits: No median or numerical p value extracted.
PER-826 monotherapy
Model: Female NOD/SCID PER-826 xenografts; n = 8 per group.
Treatment course: Started day 18 after cell injection, corresponding to 1% human CD19+CD45+ cells in bone marrow.
Reported limits: No median or numerical p value extracted.
Methods and source locations

Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: carfilzomib

Model-specific mouse findings; exact cyclodextrin assignment remains unknown. No salt conversion or Adooq material validation.

Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section; Figure 4A,B and caption

Event-free survival in PER-785 and PER-826 xenografts: Log-rank test. Methods define individual EFS from treatment initiation to leukemia-related humane endpoint; Figure 4 axes instead display days post injection. No exact p value or median survival digitized. — Figure 4A,B image/caption; Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section

PER-785 monotherapy · Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section; Figure 4A,B and caption

PER-826 monotherapy · Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section; Figure 4A,B and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 868540-17-4
Applications Proteasome inhibitor
Formula C40H57N5O7
Molecular Weight 719.9
Synonyms PR-171-007; PR-171
SMILES
CC(C)C[C@@H](C(=O)[C@]1(CO1)C)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC3=CC=CC=C3)NC(=O)CN4CCOCC4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 46 mg/mL (63.89 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
2% DMSO+30% PEG 300+2%Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Carfilzomib (PR-171) Research References

  1. [1] Deborah J. Kuhn, Qing Chen, Peter M. Voorhees, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma Blood (2007). PMID: 17591945 DOI: 10.1182/blood-2007-01-065888 Source material
  2. [2] Amanda F Baker, Neale T Hanke, Barbara J Sands, et al. Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models Journal of Experimental & Clinical Cancer Research (2014). PMID: 25612802 DOI: 10.1186/s13046-014-0111-8 Source material
  3. [3] Laurence C. Cheung, Rebecca de Kraa, Joyce Oommen, et al. Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia Frontiers in Oncology (2021). PMID: 33937032 DOI: 10.3389/fonc.2021.631594 Source material

Publications

9 publications citing this product

  1. Alireza Saedi, .et al. , J Prev Complement Med, 2025, 4(1): 26-34
  2. Mohammad Reza Hajinezhad, .et al. , Discov Nano, 2025, Aug 14;20(1):135 PMID: 40804566
  3. Zahra Mirzaei, .et al. , BMC Complement Med Ther, 2025, Jan 22;25(1):15 PMID: 39844241
  4. Andrew Thorne, .et al. , PLoS One, 2023, Jun 8;18(6):e0286783 PMID: 37289679
  5. Mahmood Barani, .et al. , J Drug Deliv Sci Technol, 2023, 81: 104268
  6. Ori Kalid, .et al. , Chem Biol Drug Des, 2022, Mar 24 PMID: 35322538
  7. Abbas Rahdar, .et al. , Journal of Molecular Liquids, 2022, 346: 118271
  8. Sadegh Zarei, .et al. , J Appl Biotechnol Rep, 2019, June;6(2):45-49
  9. Fujita KI, .et al. , J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358

Added to your cart

View Cart Checkout
Loading...